Incannex completes positive pre-IND meeting for traumatic brain injury candidate
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
List view / Grid view
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
The findings provide insight into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.
Researchers have found that the GDF15 cytokine could have beneficial effects on the metabolism and reduce obesity.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
Using cryo-EM, the researchers found that the B-cell receptor interacts with further receptors, thus controlling its signal transduction.
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
A team of scientists have 3D bioprinted breast cancer tumours and treated them in a new study, offering greater understanding of the disease.
Although Cordyceps mushrooms are challenging to cultivate, researchers have shown that they can be grown on edible insects to exploit their strong therapeutic potential.
The team from Hangzhou Dianzi University developed a three-dimensional-stacked multi-stage inertial microfluidic sort chip to enrich and separate CTCs.
Trinity College Dublin has developed a new technique that accurately determines the state of macrophages.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
Texas Biomed and The Access to Advanced Health Institute have been granted $3.5 million to initiate tuberculosis vaccine research, which includes using genetically diverse animal models.
A new study has revealed that activating the RORβ protein could lead to a possible treatment and prevention for osteoarthritis.